These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37627223)

  • 1. Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
    Karmokar A; Sargeant R; Hughes AM; Baakza H; Wilson Z; Talbot S; Bloomfield S; Leo E; Jones GN; Likhatcheva M; Tobalina L; Dean E; Cadogan EB; Lau A
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
    Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
    Gulliver C; Hoffmann R; Baillie GS
    Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
    Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
    Southgate HED; Chen L; Tweddle DA; Curtin NJ
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32354033
    [No Abstract]   [Full Text] [Related]  

  • 6. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
    Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
    Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
    Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
    Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Bryant HE; Helleday T
    Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ataxia telangiectasia mutated (ATM) is dispensable for endonuclease I-SceI-induced homologous recombination in mouse embryonic stem cells.
    Rass E; Chandramouly G; Zha S; Alt FW; Xie A
    J Biol Chem; 2013 Mar; 288(10):7086-95. PubMed ID: 23355489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
    Saha J; Wang M; Cucinotta FA
    DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
    Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
    J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway.
    Kwok M; Davies N; Agathanggelou A; Smith E; Petermann E; Yates E; Brown J; Lau A; Stankovic T
    Lancet; 2015 Feb; 385 Suppl 1():S58. PubMed ID: 26312880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic Analysis of ATM Protein Kinase in DNA Double-Strand Break Formation and Repair.
    Mian E; Wiesmüller L
    Methods Mol Biol; 2017; 1599():317-334. PubMed ID: 28477129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents.
    Haince JF; Kozlov S; Dawson VL; Dawson TM; Hendzel MJ; Lavin MF; Poirier GG
    J Biol Chem; 2007 Jun; 282(22):16441-53. PubMed ID: 17428792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells.
    Martín-Guerrero SM; Casado P; Muñoz-Gámez JA; Carrasco MC; Navascués J; Cuadros MA; López-Giménez JF; Cutillas PR; Martín-Oliva D
    Exp Eye Res; 2019 Nov; 188():107790. PubMed ID: 31494107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Repair Inhibitors Potentiate Fractionated Radiotherapy More Than Single-Dose Radiotherapy in Breast Cancer Cells.
    Wong WK; Guerra Liberal FDC; McMahon SJ
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
    Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
    Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
    Williamson CT; Kubota E; Hamill JD; Klimowicz A; Ye R; Muzik H; Dean M; Tu L; Gilley D; Magliocco AM; McKay BC; Bebb DG; Lees-Miller SP
    EMBO Mol Med; 2012 Jun; 4(6):515-27. PubMed ID: 22416035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ATR in cancer medicine.
    Sundar R; Brown J; Ingles Russo A; Yap TA
    Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.